Auxilium Pharmaceuticals — Investor Presentation (August 2010)
50 slides from Auxilium Pharmaceuticals's investor presentation, Aug 11, 2010
Slide 1: August 2010
August 2010 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates
Slide 4: XIAFLEX (collagenase clostridium histolyticum)
AlArLEX collagenase clostridium histolyticum
Slide 5: XIAFLEX – Unique Blockbuster Opportunity
XIAFLEX – Unique Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: — Approved on February 2, for Dupuytren’s Contracture in U.S. — Phase III trial in Peyronie’s disease expected to start by end of • Well-characterized mode of action • World
Slide 6: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery has been th
Slide 7: Treatment Options Historically Limited to Invasive Surgery
Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Needle fasciotomy/ aponeurotomy • Amputation • Non-surgical options > Splinting > Physical therapy > Corticosteroids
Slide 8: It Is About the Patient
It Is About the Patient Pre-XIAFLEX treatment 30 days post-single injection of XIAFLEX Immediately post-operative Intra-operative open fasciectomy Pictures courtesy of Dr. Clayton Peimer
Slide 9: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture
Slide 10: A Significant Number of Dupuytren's Contracture Patients Benefited from XIAFLEX
A Significant Number of Dupuytren’s Contracture Patients Benefited from Treatment with XIAFLEX
Slide 11: Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach N=248 N=125 Keith Denkler, M.D. Plast. Reconstr. Surg., 115802, 2005 Dupuytren’s Fasciectomies in 60 Consecutive Digits using lidocaine with epinephrine and no tourniquet Hurst et al. NEJM 2009
Slide 12: XIAFLEX Was Well-Tolerated in Phase III Studies
XIAFLEX Was Well-Tolerated in Phase III Studies • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies • Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of
Slide 13: Contracture Recurrence Affects Patients
Contracture Recurrence Affects Patients • The earliest reports of recurrence for surgery were seen in 22% of female and 19% of male Dupuytren’s contracture patients at a mean of months following fasciectomy . Additionally, a rate of up to 34% has been reported within the first years following surger
Slide 14: Two Year Recurrence Rate of 19.3% for XIAFLEX
Two Year Recurrence Rate of 19.3% for XIAFLEX ® in Dupuytren’s Contracture All Joints MP Joints PIP Joints Patients from All Phase III Studies (n=950) 1,568 Patients Enrolled in Extension Study (n=634) 1,065 Patients Successfully Treated and Enrolled in Extension Study (n=474) 619* 449* Joints with
Slide 15: Launch Update Through July 2010
Launch Update Through July 2010
Slide 16: Key Objectives for U.S. XIAFLEX Launch in 2010
Key Objectives for U.S. XIAFLEX Launch in 2010 • Position XIAFLEX as a paradigm changing non-surgical treatment alternative for physicians, payers and patients • Achieve high awareness among targeted physicians and diagnosed patients • Get targeted physicians through the sales cycle – from interest
Slide 17: Targeting the Eligible Patient Population Should Drive U.S. Market Development
Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data Based Projections (BESS database used, Medicare 5% database also use
Slide 18: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini
Slide 19: Unique Sales Cycle for Targeted Physicians
Unique Sales Cycle for Targeted Physicians Physician Interest, Training & Enrollment Successful XIAFLEX XPERIENCE
Slide 20: Changing Treatment Paradigm and Reimbursement Cycle
Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate Prior to treatment decision Physician must go through: •Awareness •Interest •Training / Enrollment into XIAFLEX XPERIENCE program •Reimbursement education / comfort •Patient Identification / counseling 11 – 21 week
Slide 21: Reimbursement Processes Are New to Target Physicians
Reimbursement Processes Are New to Target Physicians • Accounts need customized support every step of the way • Miscellaneous J and CPT codes being used; component and bundled approaches are being accepted • C-code for institutional use effective as of July 1, 2010 • CMS has recommended a J-Code for
Slide 22: Over 1,700 physicians and 1,200 sites have enrolled
Over 1,700 physicians and 1,200 sites have enrolled Feb Mar Apr May Jun Jul PHYSICIANS SITES
Slide 23: Leading Indicators Trending Positively - Cumulative Call Center Volume
Leading Indicators Trending Positively - Cumulative Call Center Volume
Slide 24: Leading Indicators Trending Positively - Cumulative Unique Sites Ordering
Leading Indicators Trending Positively - Cumulative unique sites that have ordered XIAFLEX number of sites Mar Apr May Jun Jul
Slide 25: Some Sites Moving from Test Drive to Increasing Usage
Some Sites Moving from Test Drive to Increasing Usage Injections per Site
Slide 26: ~91% of insured lives have access
~91% of insured lives have access
Slide 27: Out of Pocket Costs In Line With Expectations
Out of Pocket Costs In Line With Expectations % Of Treatment Cost Paid by Patient A significant portion of Medicare patients with a 20% liability have secondary insurance, which may cover a portion of this cost 53% 6% 8% 8% 23% 2% 0% 10% 20% 30% 40% 50% 60% 0% Up to 2% 2.1-9.9% 10-19.9% 20% >20%
Slide 28: Distribution Network is Operating Smoothly
Distribution Network is Operating Smoothly
Slide 29: Direct to Patient Program Launching
Direct to Patient Program Launching
Slide 30: Other Patient Programs Launching
Other Patient Programs Launching • XIAFLEX facebook.com webpage • XIAFLEX.com re-design • XIAFELX and Dupuytren’s contracture WedMD pages • Handraisers.com
Slide 31: We Believe Launch Strategy Is Sound
We Believe Launch Strategy Is Sound: • Product efficacy and safety are consistent with clinical data • Access to targeted physicians is good • Usage is characterized by “test driving”, which is typical for paradigm changing treatment • Payers willing to provide access to drug and procedures • All di
Slide 32: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence Based on literature, ~ 6M to 11M patients in U.S. have a Dupuytren’s pit, nodule or cord, but only ~ 300,000 new patients annually diagnosed in U.S. • Sustainable patient pool New patients within an agei
Slide 33: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug designation granted on May 23, 1996 provides exclusivity for 7 years post-approval in February 2010 • Market Exclusivity expected in U.S. for 12 years post-approval, per 2010 Patient Protection and Affordable Care Act • Market Excl
Slide 34: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/
Slide 35: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men > Actual prevalence may be higher, based on autopsies • Prevalence rate increases with age > The average age of disease onset is 53 years • High association with other diseases such as: >
Slide 36: Current Surgical Options Are the Treatment of Last Resort
Current Surgical Options Are theTreatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated
Slide 37: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 38: Promising Phase IIb Data in Peyronie's Disease
Promising Phase IIb Data in Peyronie’s Disease • Overall – Significant XIAFLEX effect – Reduction of penile curvature – Improvement in Peyronie’s Disease Bother (PRO Domain) • XIAFLEX With Modeling – Significant effect in both penile curvature and Peyronie’s disease bother endpoints • XIAFLEX Withou
Slide 39: Strategic Partnership with Pfizer for XIAFLEX in EU
Strategic Partnership with Pfizer for XIAFLEX in EU • Strong working relationship with goal to obtain EMA approval • Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. • Pfizer is primarily responsible for: European
Slide 40: Testim 1% Testosterone Gel
Testim ® 1% Testosterone Gel
Slide 41: Testim Maintains Double-Digit Growth in TRT Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad
Slide 42: Patient Results Were Proven in Clinical Studies
Patient Results Were Proven in Clinical Studies • 16 clinical studies involving approx. 1,800 patients > largest placebo-controlled study ever conducted • Clinical trial of Testim ® vs. AndroGel ® > Testim provides 30% higher testosterone absorption (p<0.001)
Slide 43: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Gel Segment Growth ($) June 2010 L12M: 29.6%
Slide 44: Continuing Track Record of Consistent Revenue Growth
Continuing Track Record of Consistent Revenue Growth
Slide 45: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims for
Slide 46: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part
FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers
Slide 47: 2010 Financial Results and 2010 Guidance
Testim Revenues $91.6 $72.1 $185-195 XIAFLEX Revenues $4.3 $1.8 N/A R&D Expense* $19.6 $27.3 $50-60 SG&A Expense* $77.3 $55.8 $160-170 Net Loss ($22.1) ($26.0) N/A Stock – Based Comp Expense (* included) $8.4 $9.4 $22-25 Cash & Cash Equivalents $165.0 2010 Financial Results and 2010 Guidance ($ Mill
Slide 48: Auxilium's Plan to Provide Visibility on XIAFLEX Launch
Auxilium’s Plan to Provide Visibility on XIAFLEX Launch • For 3Q 2010, we anticipate that XIAFLEX net revenues will be in the range of $5.5 million to $6.5 million, including approximately $1.1 million in revenue recognized from milestones previously received under the Pfizer contract. • We will con
Slide 49: Strategic Priorities in 2010
Strategic Priorities in 2010 • Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; • Support Pfizer in the ongoing regulatory review of the EU Dupuytren’s submission and prepare for their eventual launch; • Commence phase III for XIAFLEX in Peyronie’s disease by year end of 2010;
Slide 50: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates
Auxilium Pharmaceuticals — Investor Presentation (August 2010) on 6ix